頂尖納米醫療有限公司

ACE NanoMed is a Research and Development Company aiming to commercialize innovative therapeutics with highly specific targeting effect to Epstein-Barr virus (EBV)-associated malignancies.

www.acenanomed.com

發展階段｜STAGE OF DEVELOPMENT: Launched

團隊成員｜Team Member(s):

羅國煒 85崇基生物；87研究院生物；97研究院病理解剖及細胞學哲學博士 / 病理解剖及細胞學系教授
曾智敏 03逸夫分子生物技術學；05研究院中醫藥學 / 病理解剖及細胞學系助理教授
鄭路 93聯合醫學科學；96聯合內外全科醫學
曾智仁 94崇基工商管理
梁曦文 20新亞生物化學；22研究院病理解剖及細胞學
吳蔓 20研究院病理解剖及細胞學哲學博士

We utilize the special association of EBV infection to these malignancies to invent mRNA-based and aptamer-based nanoparticles for therapeutic purposes.

Therapeutic Product #1:

“Anti-tumor immune commander” – mRNA therapeutic vaccine which encodes EBV antigens for training anti-cancer T cell responses to EBV-infected cancer cells.

Therapeutic Product #2:

“Target killer” – DNA aptamers which can deliver the traditional chemodrugs specifically to EBV-infected cancer cells.

Therapeutic Product #3:

“Smart bomb” – mRNA lipid-nanoparticles which can elicit cytolytic virus activation (CLVA) therapy for specific killing of EBV-positive cancer cells.

利用 EBV 感染與這些惡性腫瘤的特殊關聯來發明新型納米藥物，包括mRNA-脂質納米顆粒和適配體。

治療產品#1：

“抗腫瘤免疫指揮官”—編碼 EBV 抗原的 mRNA 治療疫苗，用於訓練抗癌 T 細胞對 EBV 感染的癌細胞的反應。

治療產品#2：

“目標殺手”—DNA適體，可以將傳統化療藥物特異性遞送至感染EB病毒的癌細胞。

治療產品#3：

“智能炸彈”—mRNA 脂質納米顆粒，可引發溶細胞病毒激活 (CLVA) 療法，特異性殺死 EBV 陽性癌細胞。

如何解決市場痛點 | RESPONSE TO MARKET PAIN POINTS:

Problems:

Whenever systemic chemotherapy being applied in primary, recurrent and metastatic cases of EBV-associated cancers, patients may suffer from acute toxicity including hearing loss, swallowing problems and others; and late toxicity including cranial neuropathy, temporal lobe necrosis, aspiration pneumonia etc. More effective and less-toxic treatment regimens are always in need for better caring of cancer patients.

Our solutions:

Our targeting mRNA-based and DNA-based nanomedicines can target to EBV-associated cancer cells, therefore the normal cells will not be affected. The patients will suffer from much less side effects, and can live a much better quality of life during and after treatment.

市場痛點

每當全身化療應用於EBV相關癌症的原發性、復發性和轉移性病例時，患者可能會出現急性毒性反應，包括聽力損失、吞嚥問題等；晚期毒性包括顱神經病變、顳葉壞死、吸入性肺炎等。為了更好地護理癌症患者，需要更有效、更靶向、毒性更小的治療方案。

我們的解決方案

我們的 mRNA 和 DNA 的靶向納米藥物可以靶向 EBV 相關癌細胞，因此正常細胞不會受到影響，並大大減少副作用，患者在治療期間和治療後可以過上好的生活質量。

現時或曾經參與之創業培育計劃｜ INCUBATION PROGRAMME:

TSSSU (2023 – 2024)

現在尋找… | LOOKING FOR…:

資金 Funding
創業夥伴 Partners
曝光機會 Visibility and Exposure

宣傳資料｜ PROMOTIONAL MATERIALS:

ACE-NanoMed-EN.pdf
ACE-NanoMed-TC.pdf
ACE-NanoMed-SC.pdf